Zacks Research Analysts Raise Earnings Estimates for STERIS plc (NYSE:STE)

STERIS plc (NYSE:STE) – Zacks Research lifted their Q2 2026 earnings per share estimates for shares of STERIS in a report released on Wednesday, September 25th. Zacks Research analyst R. Department now forecasts that the medical equipment provider will earn $2.41 per share for the quarter, up from their previous estimate of $2.40. The consensus estimate for STERIS’s current full-year earnings is $9.05 per share. Zacks Research also issued estimates for STERIS’s Q3 2026 earnings at $2.32 EPS.

STERIS (NYSE:STE) last announced its earnings results on Tuesday, August 6th. The medical equipment provider reported $2.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.98 by $0.16. STERIS had a return on equity of 13.85% and a net margin of 7.36%. The firm had revenue of $1.28 billion during the quarter, compared to analysts’ expectations of $1.27 billion. During the same quarter in the prior year, the business earned $2.00 earnings per share. The company’s revenue was down .4% on a year-over-year basis.

A number of other equities analysts have also commented on the company. KeyCorp lifted their price objective on STERIS from $255.00 to $265.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 3rd. JMP Securities reaffirmed a “market outperform” rating and issued a $265.00 price target on shares of STERIS in a research report on Wednesday, August 7th. StockNews.com upgraded STERIS from a “hold” rating to a “buy” rating in a report on Tuesday, August 13th. Needham & Company LLC restated a “hold” rating on shares of STERIS in a research note on Thursday, August 8th. Finally, Stephens reiterated an “overweight” rating and set a $260.00 target price on shares of STERIS in a research note on Wednesday, August 7th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $246.00.

STERIS Stock Performance

Shares of STE opened at $239.05 on Friday. The company has a market capitalization of $23.58 billion, a PE ratio of 62.58 and a beta of 0.83. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.33 and a quick ratio of 1.49. STERIS has a one year low of $195.47 and a one year high of $248.24. The company’s fifty day moving average price is $237.51 and its 200 day moving average price is $225.77.

Hedge Funds Weigh In On STERIS

Hedge funds have recently added to or reduced their stakes in the company. Massachusetts Financial Services Co. MA boosted its stake in shares of STERIS by 13.7% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 6,442,805 shares of the medical equipment provider’s stock valued at $1,414,453,000 after purchasing an additional 778,613 shares during the last quarter. APG Asset Management US Inc. acquired a new position in STERIS in the fourth quarter valued at about $74,963,000. Sustainable Growth Advisers LP lifted its stake in STERIS by 23.5% in the first quarter. Sustainable Growth Advisers LP now owns 1,485,578 shares of the medical equipment provider’s stock valued at $333,988,000 after buying an additional 282,387 shares during the period. Impax Asset Management Group plc boosted its holdings in STERIS by 29.7% during the second quarter. Impax Asset Management Group plc now owns 1,150,517 shares of the medical equipment provider’s stock worth $251,663,000 after buying an additional 263,383 shares during the last quarter. Finally, American Century Companies Inc. grew its position in shares of STERIS by 1,946.3% during the 2nd quarter. American Century Companies Inc. now owns 270,311 shares of the medical equipment provider’s stock worth $59,344,000 after buying an additional 257,101 shares during the period. Institutional investors own 94.69% of the company’s stock.

Insider Buying and Selling at STERIS

In other news, CFO Michael J. Tokich sold 23,332 shares of the company’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $247.00, for a total value of $5,763,004.00. Following the sale, the chief financial officer now owns 42,930 shares of the company’s stock, valued at approximately $10,603,710. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, Director Christopher S. Holland sold 473 shares of the company’s stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $239.68, for a total transaction of $113,368.64. Following the transaction, the director now directly owns 582 shares in the company, valued at $139,493.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Michael J. Tokich sold 23,332 shares of the company’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $247.00, for a total value of $5,763,004.00. Following the transaction, the chief financial officer now directly owns 42,930 shares in the company, valued at approximately $10,603,710. The disclosure for this sale can be found here. Company insiders own 1.14% of the company’s stock.

STERIS Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 20th. Stockholders of record on Thursday, September 5th were issued a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a dividend yield of 0.95%. This is an increase from STERIS’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend was Thursday, September 5th. STERIS’s dividend payout ratio (DPR) is presently 59.69%.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.